VolitionRx (NYSE:VNRX) vs. Quidel (NASDAQ:QDEL) Financial Contrast

VolitionRx (NYSE:VNRXGet Rating) and Quidel (NASDAQ:QDELGet Rating) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, earnings, profitability, institutional ownership, dividends, analyst recommendations and valuation.

Insider & Institutional Ownership

11.1% of VolitionRx shares are owned by institutional investors. Comparatively, 92.9% of Quidel shares are owned by institutional investors. 15.4% of VolitionRx shares are owned by insiders. Comparatively, 2.7% of Quidel shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares VolitionRx and Quidel’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
VolitionRx -15,827.93% -129.70% -91.65%
Quidel 43.26% 56.46% 44.21%

Analyst Recommendations

This is a summary of recent recommendations for VolitionRx and Quidel, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
VolitionRx 0 0 1 0 3.00
Quidel 0 0 2 1 3.33

Quidel has a consensus price target of $143.00, suggesting a potential upside of 42.15%. Given Quidel’s stronger consensus rating and higher probable upside, analysts plainly believe Quidel is more favorable than VolitionRx.

Risk and Volatility

VolitionRx has a beta of 1.65, indicating that its stock price is 65% more volatile than the S&P 500. Comparatively, Quidel has a beta of 0.02, indicating that its stock price is 98% less volatile than the S&P 500.

Valuation and Earnings

This table compares VolitionRx and Quidel’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
VolitionRx $90,000.00 1,374.63 -$26.82 million ($0.52) -4.42
Quidel $1.70 billion 2.48 $704.23 million $23.69 4.25

Quidel has higher revenue and earnings than VolitionRx. VolitionRx is trading at a lower price-to-earnings ratio than Quidel, indicating that it is currently the more affordable of the two stocks.

Summary

Quidel beats VolitionRx on 12 of the 15 factors compared between the two stocks.

VolitionRx Company Profile (Get Rating)

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. It sells Nu.Q that detect cancer; Nu.Q Nets, monitoring the immune system; Nu.Q Vet cancer screening test for veterinary applications; Nu.Q Capture capturing and concentrating samples for more accurate diagnosis; and Nu.Q Discover, a solution to profiling nucleosomes. The company operates Nucleosomics a technology platform for blood test. VolitionRx Limited is based in Austin, Texas.

Quidel Company Profile (Get Rating)

Quidel Corporation develops, manufactures, and markets diagnostic testing solutions for applications in infectious diseases, cardiology, thyroid, women's and general health, eye health, gastrointestinal diseases, and toxicology worldwide. It offers Sofia and Sofia 2 fluorescent immunoassay systems; QuickVue, a lateral flow immunoassay products; and InflammaDry and AdenoPlus, a POC products to detect infectious and inflammatory diseases and conditions of the eye. The company also provides Triage MeterPro, a portable testing platform that enables physicians to promote enhanced health outcomes, as well as the detection of certain drugs of abuse; Triage BNP test for use on Beckman Coulter lab analyzers; and Triage TOX drug screen, which provides results for the presence of drug and/or the major metabolites in urine. In addition, it offers traditional cell lines, specimen collection devices, media, and controls for use in laboratories that culture and test for various human viruses, including respiratory and herpes family viruses; and cell-based products comprising tubes, shell vials, and multi-well plates. Further, the company provides biomarkers, which include clinical and research products for the assessment of osteoporosis and the evaluation of bone resorption/formation; and enzyme linked immunosorbent assays and reagents for the detection of activation products. Additionally, it offers Lyra molecular real-time polymerase chain reaction assays; Solana, an amplification and detection system; Savanna, an automated in vitro molecular diagnostic platform; and Virena, a wireless cellular data management and surveillance system. The company markets its products through distributors and direct sales force for use in physician offices, hospitals, clinical laboratories, reference laboratories, universities, retail and urgent care clinics, pharmacies, and wellness screening centers. Quidel Corporation was incorporated in 1979 and is headquartered in San Diego, California.

Receive News & Ratings for VolitionRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VolitionRx and related companies with MarketBeat.com's FREE daily email newsletter.